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Abstract
Introduction The purpose of this study was to quantitatively
evaluate the contribution of synovial lymphoid aggregates to
autoantibody (rheumatoid factor [RF] and anti-cyclic citrullinated
peptide [anti-CCP]) and total immunoglobulin (IgG and IgM)
production in rheumatoid arthritis (RA) patients and the effect
thereon of the B-cell-depleting antibody, rituximab, in the ARISE
(Assessment of Rituximab's Immunomodulatory Synovial
Effects) trial.
Methods Autoantibodies as well as total IgM and IgG were
quantified by enzyme-linked immunosorbent assay in extracts of
synovial tissues and matched serum from patients with RA or
osteoarthritis (OA). Synovial biopsies and serum were obtained
at baseline and 8 weeks following rituximab therapy in 14 RA
patients. A synovial/serum index (SSI) was calculated as the
ratio of synovial to serum antibody/albumin, with values above 1
representing synovial enrichment. Lymphoid aggregates were
evaluated histologically.
Results Anti-CCP IgG, but not RF-IgM, was significantly
enriched in RA synovia compared with serum. Total IgM and IgG
were also enriched in RA, but not in OA. SSI correlated
significantly with mRNA content for both IgM and IgG,
demonstrating that it reflected synovial immunoglobulin
production. RA synovia with lymphocyte aggregates contained
significantly elevated RF-IgM and anti-CCP IgG compared with
tissues with diffuse lymphoid infiltration. Rituximab treatment did
not affect synovial autoantibody or total immunoglobulin SSI
overall. However, in aggregate-containing tissues, rituximab
significantly reduced total IgM and IgG SSI as well as IgM and
IgG1 mRNA. Surprisingly, RF-IgM and anti-CCP IgG SSIs were
unchanged by rituximab in aggregate-containing synovia.
Conclusions Combined with earlier observations that synovial
lymphoid aggregates are unaltered by rituximab treatment, these
data suggest that lymphoid aggregates may provide a protective
niche for autoantibody-producing cells.
Trial Registration The ARISE trial is registered at
ClinicalTrials.gov as number NCT00147966.
Introduction
Rheumatoid arthritis (RA) is associated with the presence of
certain circulating autoantibodies, such as rheumatoid factors
(RFs) and anti-cyclic citrullinated peptide (anti-CCP) [1]. The
latter has received recent attention because elevated levels
can precede development of joint symptoms and because it
acts synergistically with the shared HLA-DR epitope to
enhance the risk of developing RA [2]. A contribution of B cells
and their products to the pathogenesis of RA is supported by
the clinical success of rituximab, a B-cell-depleting antibody
targeting CD20. Whereas long-lived plasma cells are unaf-
fected by rituximab, circulating B cells are nearly completely
depleted [3,4] and modest, albeit significant, decreases in cir-
culating RF and anti-CCP antibodies are observed [5]. The
anti-CCP: anti-cyclic citrullinated peptide; ARISE: Assessment of Rituximab's Immunomodulatory Synovial Effects; CI: confidence interval; DAS28: 
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effect of rituximab on the rheumatoid synovium is just
beginning to be characterized. Recently, we [6] and others [7]
reported that, following rituximab treatment, synovial B cells
are depleted less effectively, and more variably, than their cir-
culating counterparts. In the subset of patients with synovial
lymphoid aggregates, rituximab treatment did not alter the
number or size of these aggregates [7]. Because such aggre-
gates are associated with elevated synovial immunoglobulin
synthesis, as determined by mRNA levels for IgG constant
regions [8], and perhaps also autoantibody synthesis, we
sought to determine the effect of rituximab treatment on syno-
vial autoantibody production.
The local synthesis of immunoglobulins and autoantibodies by
rheumatoid synovium is well appreciated but its contribution to
the circulating pool is poorly understood. Explants of rheuma-
toid synovial tissue are capable of synthesizing immunoglobu-
lins [9,10], RF [9,10], and anti-CCP IgG [11]. Similarly,
dispersed cells from rheumatoid synovia synthesize immu-
noglobulins [12,13] and RF [13-15], and synovial fluid-derived
mononuclear cells secrete anti-CCP antibodies [16]. Although
these techniques are valuable for the understanding of the
contribution of local antibody synthesis to the pathogenesis of
RA, their applicability in interventional biopsy-based clinical tri-
als is limited. Synovial tissues obtained by arthroscopy or nee-
dle biopsy typically do not yield enough tissue to recover a
sufficient amount of dispersed cells, and the viability of syno-
vial biopsies for explant cultures might be compromised when
samples have to be transported from clinical sites to the labo-
ratory. With this in mind, we developed and validated a novel
set of techniques that can be used on frozen specimens for
the measurement of autoantibodies and immunoglobulins in
paired synovial biopsies and sera obtained prior to, and follow-
ing, an intervention. These methods were used to evaluate the
effect of rituximab treatment on synovial autoantibody and
immunoglobulin production and the role of lymphoid architec-
ture on this effect.
Materials and methods
Patients
Patients with RA or osteoarthritis (OA) were included after
informed consent was obtained under approval from the Uni-
versity of California-San Diego Institutional Review Board. A
subset of patients who were part of the ARISE (Assessment
of Rituximab's Immunomodulatory Synovial Effects) clinical
trial, recently described in detail [6], received rituximab at a
dose of 1 g given intravenously over the span of 4 to 5 hours
on day 0 and again on day 14. The same joint was biopsied
prior to and 8 weeks following treatment.
Synovial tissue
Synovial tissue was collected at the time of joint replacement
surgery (knees or hips from all OA patients and the majority of
RA patients; other anatomical sites included three wrists, one
shoulder, one elbow, and one metacarpophalangeal). The tis-
sue was immediately placed on ice and transported to the lab-
oratory, and synovial tissue fragments (size 1 to 2 mm2) were
excised using a fine scalpel and snap-frozen in liquid nitrogen
in sets of six or were embedded in cryosectioning medium. For
ARISE patients, synovial tissue biopsies were obtained under
conscious sedation anesthesia from knees or wrists using
arthroscopically guided Automated Motorized Shaver technol-
ogy, a method that rapidly yields greater than 50 synovial tis-
sue fragments rich in synovial lining. Aliquots of the resulting
synovial fragments were immediately snap-frozen or embed-
ded. In some cases, a paired serum or plasma sample was
obtained at the time of surgery or biopsy. All samples were
stored at -80°C until analysis. The presence or absence of lym-
phoid aggregates was scored on hematoxylin/eosin-stained
cryosections. Tissues displaying grade 2 or 3 aggregates [17]
were considered positive for the presence of lymphoid
aggregates.
Autoantibody and immunoglobulin enzyme-linked 
immunosorbent assays
Frozen synovial fragments were weighed and immediately
placed in chilled 1-mL Kontes-Duall tissue grinders, and ice-
cold extracting buffer consisting of 1% Brij-35 detergent
(Sigma-Aldrich, St. Louis, MO, USA) in phosphate-buffered
saline with protease inhibitor cocktail (Complete Mini; Roche
Applied Science, Indianapolis, IN, USA) was added at 50 μL
per 10 mg of tissue. The mixture was ground by hand on ice
until only fibrous white insoluble material remained. After incu-
bation of the mixture for at least 10 minutes on ice, it was trans-
ferred to a microcentrifuge tube and centrifuged 10 minutes at
20,000 g and 4°C. The resulting supernatant was aliquotted
and stored at -80°C for later analysis. Total protein content in
extracts diluted 1:10 in distilled water was determined using
DC Protein Assay reagents (Bio-Rad Laboratories, Hercules,
CA, USA). Colorimetric enzyme-linked immunosorbent assay
kits were used to detect RF of the IgM subtype (RF-IgM)
(ALPCO Diagnostics, Salem, NH, USA), anti-CCP IgG
(INOVA Diagnostics, Inc., San Diego, CA, USA), anti-tetanus
IgG (ImmunoBiological Laboratories, Minneapolis, MN, USA),
total IgM and total IgG, and albumin (all from Bethyl Laborato-
ries, Montgomery, TX, USA) in synovial extracts and serum or
plasma samples diluted to yield absorbance values in the lin-
ear range of the kit. Standard curves were constructed by
regression line fitting on log(absorbance) versus log(concen-
tration). In preliminary experiments, recovery of spiked stand-
ards in synovial extracts was assessed as described earlier
[18] and found to be better than 80% in all cases. Analysis
was performed on pools of greater than six synovial tissue
fragments in order to minimize the effects of synovial hetero-
geneity [18]. For a given autoantibody or immunoglobulin ana-
lyte, synovial/serum index (SSI) was defined as the ratio of
synovial analyte/synovial albumin divided by the ratio of serum
analyte/serum albumin.Available online http://arthritis-research.com/content/10/5/R105
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Heavy chain constant region quantitative real-time 
polymerase chain reaction
Messenger RNA for heavy chain constant regions for IgM and
IgG1 was quantified by real-time TaqMan quantitative real-
time polymerase chain reaction (qPCR) using cDNA with glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH) used as a
housekeeper. We have previously established that data
derived from sets of six or more synovial tissue fragments min-
imize sampling error [19] and pools of greater than six frag-
ments were used for qPCR analysis. Resulting threshold cycle
data were normalized to standard curves constructed from
cDNA from RAMOS (IgM), ARH-77 (IgG1), and human PBMC
(GAPDH) [19], yielding cell equivalents. The ratio between the
specific cytokine and GAPDH cell equivalents (relative expres-
sion units, REU) is reported.
Statistical analysis
Data are expressed as median and quartile and were analyzed
by Wilcoxon rank sum test for comparing two unpaired
groups. The Wilcoxon sign rank test was used to test locations
of nonparametric populations. The effect by rituximab on syn-
ovial REU, autoantibody, and immunoglobulin levels is
expressed as the geometric mean ± 95% confidence interval
(CI) of percentage change pre- to post-treatment [20].
Results
Detection of autoantibodies in synovial tissue extracts
To determine whether autoantibodies were detectable in syn-
ovia, RF-IgM and anti-CCP IgG were measured in extracts
from 12 OA and 21 RA synovial tissues. Both RF-IgM and anti-
CCP IgG were detectable in the majority of RA synovial
extracts (17 of 21 in both cases) (Figure 1a). In contrast, OA
synovial extracts were largely devoid of autoantibodies. RF-
IgM was detectable in only 1 of 12 OA synovial extracts, and
none contained detectable anti-CCP IgG (Figure 1a). A dis-
ease-irrelevant antibody, anti-tetanus IgG, was detectable in
both RA and OA extracts at similar ranges (Figure 1a), sug-
gesting that there were no intrinsic differences in antibody
detectability between the two types of synovia. The large vari-
ability observed in autoantibody concentrations in RA extracts
might be explained by varying tissue serum content and/or var-
ying autoantibody concentrations in serum. To correct for
these variables, paired synovia and sera were obtained from
11 RA and 6 OA patients, and albumin levels determined
alongside antibodies to allow calculation of SSI, as described
in Materials and methods. By definition, an SSI value above 1
indicates synovial enrichment. As shown in Figure 1b, anti-
CCP IgG was significantly enriched in RA synovial extracts
compared with serum, whereas the RF-IgM SSI was not sig-
nificantly different than 1. None of the 6 OA patients was pos-
itive for either autoantibody in serum or synovial extracts, so an
OA SSI could not be calculated. However, interestingly, when
the specific activities for anti-tetanus IgG in RA and OA syno-
vial extracts were compared, levels in RA extracts were signif-
icantly higher than those in OA (Figure 1c), suggesting
enrichment of this disease-irrelevant antibody in RA synovia as
well.
Enrichment of total immunoglobulin in rheumatoid 
arthritis synovial tissue
Total IgM and IgG were quantified in serum and synovial
extracts and specific activities calculated. Both subclasses
were elevated in RA extracts compared with those in OA (Fig-
ure 2a,b). An SSI above 1 was noted in 7/11 RA and 0/11 OA
samples for IgM and in 10/11 RA and 0/11 OA samples for
Figure 1
Detection and enrichment of autoantibodies in rheumatoid arthritis (RA)  synovial extracts Detection and enrichment of autoantibodies in rheumatoid arthritis (RA) 
synovial extracts. Tissues were obtained by arthroplasty or arthroscopic 
shaver biopsy, and serum and synovial extracts were analyzed by 
enzyme-linked immunosorbent assay for antibodies of interest and albu-
min. (a) Individual levels of RF-IgM, anti-CCP IgG, and anti-tetanus IgG 
in extracts from osteoarthritis (OA) (n = 12, autoantibodies; n = 11, 
anti-tetanus) and RA (n = 21, autoantibodies; n = 14, anti-tetanus) syn-
ovial tissue, normalized to total protein concentration. Limits of detec-
tion are 4 (RF-IgM), 10 (anti-CCP IgG), and 0.3 (anti-tetanus IgG). 
Serum-normalized levels of (b) RF-IgM and anti-CCP IgG in RA syno-
vial extracts (n = 11) and (c) anti-tetanus IgG in OA (n = 6) and RA (n 
= 9) synovial extracts. In the box (interquartile range, IQR) and whisker 
(maximum and minimum) plots, the horizontal line inside the box 
denotes median and the unfilled circles denote outliers outside IQR ± 
1.5 × IQR. The asterisk denotes P = 0.019 by Wilcoxon sign rank test 
to 1 (no enrichment) for anti-CCP IgG (a), and the indicated P value 
was determined by Wilcoxon rank sum test between OA and RA for 
anti-tetanus IgG (b). The value for RF-IgM was not significantly above 1 
(P = 0.32). anti-CCP, anti-cyclic citrullinated peptide; RF-IgM, rheuma-
toid factor of the IgM subtype; SSI, synovial/serum index.Arthritis Research & Therapy    Vol 10 No 5    Rosengren et al.
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IgG. This could indicate either enhanced local production or
preferential localization to the synovium after synthesis else-
where. To distinguish between these two possibilities, qPCR
was used to determine mRNA levels for constant regions of
IgM and IgG1 heavy chains in RA and OA synovia. As seen in
Figures 2c and 2d, both were significantly higher in RA tis-
sues. Notably, significant correlations were observed between
mRNA levels and SSI for both IgM (R = 0.701; P = 0.0017;
Figure 3a) and IgG (R = 0.825; P < 0.0001; Figure 3b), indi-
cating that local synthesis contributes to synovial immunoglob-
ulin enrichment.
Autoantibodies and immunoglobulins in rheumatoid 
arthritis synovia with lymphoid aggregates
Lymphoid cell infiltrates in RA synovia can be more or less
organized. In a subset of tissues, lymphoid cells are organized
in aggregates that might function as ectopic lymphoid organs
and contribute to local autoantibody production. To examine
this possibility, the presence or absence of lymphoid aggre-
gates in 25 RA synovial tissues was determined and SSI for
RF-IgM and anti-CCP IgG calculated. Grade 2 or 3 lymphoid
aggregates were identified in cryosections of eight synovia. As
shown in Figure 4, both autoantibodies were present at signif-
icantly elevated levels in synovia containing lymphoid
Figure 2
Significant enrichment of total IgM and IgG in rheumatoid arthritis (RA)  synovia Significant enrichment of total IgM and IgG in rheumatoid arthritis (RA) 
synovia. Serum-normalized levels of (a) total IgM and (b) total IgG in 
extracts from osteoarthritis (OA) (n = 6) and RA (n = 11) synovial tis-
sue obtained by arthroplasty or arthroscopic shaver biopsy and meas-
ured by enzyme-linked immunosorbent assay for antibodies of interest 
and albumin. GAPDH-normalized message for IgM (c) and IgG1 (d) 
heavy constant region as determined by quantitative real-time polymer-
ase chain reaction in the same synovia as in (a) and (b). See Figure 1 
legend for box plot definitions. Indicated P values were determined by 
Wilcoxon rank sum test. GAPDH, glyceraldehyde-3-phosphate dehy-
drogenase; REU, relative expression units; SSI, synovial/serum index.
Figure 3
Correlation between synovial/serum index (SSI) and mRNA for total  IgM and IgG Correlation between synovial/serum index (SSI) and mRNA for total 
IgM and IgG. Correlation plots for SSI versus GAPDH-normalized 
mRNA levels for total IgM (a) and total IgG (b) in rheumatoid arthritis 
(RA) and osteoarthritis (OA) synovia. Data are from Figure 2. Correla-
tion coefficients (R) and P values were determined by Spearman rank 
correlation. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; 
REU, relative expression units.Available online http://arthritis-research.com/content/10/5/R105
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aggregates compared with synovia with diffuse lymphoid infil-
tration. In tissues with lymphoid aggregates, SSI for both
autoantibodies was above 1 (P = 0.023 and 0.008, SSI above
1 in 7/8 and 8/8, respectively, for RF-IgM and anti-CCP IgG),
whereas in tissues with diffuse infiltration the autoantibody SSI
was not different from 1 (P = 0.60 and 0.19, SSI above 1 in 5/
17 and 11/17, respectively). Total IgM and IgG were also
determined in these extracts (Figure 5). Significantly
enhanced IgM and IgG1 constant region message was
detected by qPCR in synovia with lymphoid aggregates (Fig-
ure 5a,b). In contrast, the specific activities for IgM and IgG
were similar in tissues with and without organized lymphoid
infiltration (Figure 5c,d).
Effect of rituximab on synovial autoantibody and 
immunoglobulin content
Baseline blood and synovial biopsies were collected prior to
treatment with the B-cell-depleting antibody, rituximab. Eight
weeks later, blood and synovial samples from the same joint
were obtained. As described earlier, circulating B cells were
nearly completely depleted by treatment (geometric mean
depletion 98.8%, CI 97.7% to 99.3%). A small but significant
reduction in circulating RF-IgM, anti-CCP IgG, and total IgM,
but not total IgG, was observed (Figure 6a). However, the syn-
ovial content of autoantibodies and immunoglobulins did not
change following rituximab treatment when all treated patients
were considered as a single group (Figure 6b). There was,
however, a significant reduction of IgG1 constant region mes-
sage in synovial tissues after rituximab treatment (Figure 6b).
The correlation between clinical response to rituximab, as
measured by change in disease activity score using 28 joint
counts (DAS28), and percentage change of SSI pre- to post-
treatment was examined; however, none of the autoantibodies
or total immunoglobulin examined covaried with DAS28 in a
statistically significant manner.
Differential effect of rituximab in synovial tissues 
containing lymphoid aggregates
Trial subjects were grouped according to the presence or
absence of lymphoid aggregates in their synovial biopsies
prior to rituximab treatment, and the effect of rituximab was
determined. Lymphoid aggregates were observed 8 weeks
after rituximab treatment in all synovia that contained such
aggregates prior to treatment (n = 5). The effect of rituximab
on circulating autoantibodies or total immunoglobulins did not
Figure 4
The presence of lymphoid aggregates in rheumatoid arthritis (RA) syno- via is associated with elevated synovial autoantibody levels The presence of lymphoid aggregates in rheumatoid arthritis (RA) syno-
via is associated with elevated synovial autoantibody levels. Serum-nor-
malized levels of (a) RF-IgM and (b) anti-CCP IgG in extracts from RA 
synovia with (Aggr, n = 8) or without (No aggr, n = 17) lymphoid aggre-
gates. Tissues were obtained by arthroplasty or arthroscopic shaver 
biopsy, and extracts were analyzed by enzyme-linked immunosorbent 
assay for antibodies of interest and albumin. See Figure 1 legend for 
box plot definitions. Indicated P values were determined by Wilcoxon 
rank sum test. anti-CCP, anti-cyclic citrullinated peptide; RF-IgM, rheu-
matoid factor of the IgM subtype.
Figure 5
The presence of lymphoid aggregates in rheumatoid arthritis (RA) syno- via is associated with elevated total immunoglobulin message, but not  protein The presence of lymphoid aggregates in rheumatoid arthritis (RA) syno-
via is associated with elevated total immunoglobulin message, but not 
protein. GAPDH-normalized message for IgM (a) and IgG1 (b) heavy 
constant region in cDNA from RA synovia with (Aggr, n = 8) or without 
(No aggr, n = 17) lymphoid aggregates. Serum-normalized levels of (c) 
total IgM and (d) total IgG in extracts from the same synovia as in (a) 
and (b). Tissues were obtained by arthroplasty or arthroscopic shaver 
biopsy, and cDNA was analyzed by quantitative real-time polymerase 
chain reaction (a, b). Extracts were analyzed by enzyme-linked immuno-
sorbent assay for antibodies of interest and albumin (c, d). See Figure 1 
legend for box plot definitions. Indicated P values were determined by 
Wilcoxon rank sum test. GAPDH, glyceraldehyde-3-phosphate dehy-
drogenase; REU, relative expression units; SSI, synovial/serum index.Arthritis Research & Therapy    Vol 10 No 5    Rosengren et al.
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differ based on the presence of synovial aggregates. However,
in synovia containing lymphoid aggregates, substantial and
significant reductions of total IgM and IgG were noted in
response to rituximab, whether assayed by constant region
mRNA levels (Figure 7a) or by protein content (Figure 7b).
Such decreases were not observed in synovial tissues lacking
lymphoid aggregates (Figure 7). Despite the significant effect
on total immunoglobulin content in aggregate-containing syn-
ovia, neither RF-IgM nor anti-CCP IgG in synovial tissues were
decreased by rituximab, whether they contained lymphoid
aggregates or not (Figure 7c).
Discussion
Rituximab is a B-cell-depleting antibody approved for treat-
ment of anti-tumor necrosis factor (TNF)-resistant RA but its
mechanism of action is unclear. In the synovium, B cells and
immunoglobulin constant region mRNA are significantly low-
ered in patients with a substantial (at or above American
College of Rheumatology 50%) clinical response to rituximab
[6]. The effect of rituximab on synovial autoantibody synthesis
has not been previously reported, although circulating autoan-
tibodies are known to be only m o d e s t l y  a f f e c t e d  [ 5 ] .  T h i s
paper describes the effect of rituximab on synovial autoanti-
body and immunoglobulin levels, as determined by a novel
approach for the antibody measurement, in synovial biopsies
from patients with RA.
In cross-sectional feasibility studies, both RF and anti-CCP
were easily detected in the majority of the RA synovial extracts.
The variability among patients was very large (80- to 100-fold
when expressed without regard to serum content). To account
for variable levels in serum and also to normalize for differing
amounts of serum in the tissues, an albumin-normalized SSI
was formulated whereby a value above 1 by definition
Figure 6
Effect of rituximab on circulating and synovial autoantibodies and  immunoglobulin Effect of rituximab on circulating and synovial autoantibodies and immu-
noglobulin. (a) Circulating levels of autoantibodies and total IgM and 
IgG 8 weeks after rituximab treatment are expressed as percentage of 
pretreatment levels. (b) Serum-normalized levels of autoantibodies and 
total IgM and IgG determined by enzyme-linked immunosorbent assay, 
or mRNA levels of IgM and IgG1 heavy constant region determined by 
quantitative real-time polymerase chain reaction, in synovial biopsies 8 
weeks after rituximab treatment are expressed as percentage of pre-
treatment levels. Data are expressed as geometric mean ± 95% confi-
dence interval (CI) of 14 subjects. Asterisks denote that 95% CI 
excludes 0% change (stippled line). anti-CCP, anti-cyclic citrullinated 
peptide; RF-IgM, rheumatoid factor of the IgM subtype.
Figure 7
Rituximab selectively lowers total immunoglobulin synthesis but not  autoantibody content in rheumatoid arthritis (RA) synovia containing  lymphoid aggregates Rituximab selectively lowers total immunoglobulin synthesis but not 
autoantibody content in rheumatoid arthritis (RA) synovia containing 
lymphoid aggregates. (a) GAPDH-normalized synovial message for 
IgM and IgG1 heavy constant region in RA synovial biopsies with 
(Aggr, n = 5) or without (None, n = 9) lymphoid aggregates 8 weeks 
after rituximab treatment. Serum-normalized levels of (b) total IgM and 
total IgG and (c) RF-IgM and anti-CCP IgG in extracts from the same 
synovia as in (a). Data are expressed as geometric mean ± 95% confi-
dence interval (CI) of post-treatment levels relative to pretreatment lev-
els. Asterisks denote that 95% CI excludes 0% change (stippled line). 
anti-CCP, anti-cyclic citrullinated peptide; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; RF-IgM, rheumatoid factor of the IgM sub-
type; SSI, synovial/serum index.Available online http://arthritis-research.com/content/10/5/R105
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indicates synovial enrichment (that is, a higher level than would
be expected if the entire amount in synovium was associated
with its serum content). A similar approach was employed ear-
lier in synovial fluid [21]. Naturally, enrichment does not
directly indicate synovial synthesis and alternatively can reflect
accumulation of antibodies or immunoglobulin in the synovial
environment for a variety of other reasons. However, signifi-
cant correlations between total immunoglobulin mRNA levels
(as determined by qPCR) and SSI were observed, indicating
that locally synthesized antibodies provide an important com-
ponent of SSI. In addition, this correlation suggests that the
sampling methods developed for other synovial protein [18]
and mRNA [19] analysis are applicable to immunoglobulin
measurements.
Using this method, both anti-CCP IgG and anti-tetanus IgG as
well as total IgM and IgG were found to be significantly
enriched in RA synovia, whereas the value for RF-IgM did not
differ significantly from 1. The reason for the RF-IgM results is
unclear; certainly, production of RFs by synovial tissue has
been demonstrated earlier [9,10,13-15], but much larger
amounts made in lymph nodes and spleen might mask the syn-
ovial contribution to blood levels. More interesting, however, is
the synovial enrichment of anti-tetanus IgG, an antibody irrele-
vant to the pathology of RA but earlier shown to be present in
RA synovia [22]. This observation supports the idea that the
RA synovium provides a favorable environment for any anti-
body-producing cell. This notion stems from observations that
fibroblast-like synoviocytes support in vitro survival and
differentiation of B cells [23,24]. Also, the inflamed RA syn-
ovium releases CXCL12 (SDF-1), interleukin-6, TNF, BAFF
(B-cell activating factor of TNF family), and APRIL (a prolifera-
tion-inducing ligand), all known to promote the accumulation
and survival of long-lived plasma cells, which are normally
found mainly in bone marrow [25].
Lymphocytic infiltrates in rheumatoid synovia can be diffuse or
alternatively occur in more or less organized aggregates,
sometimes resembling germinal centers [26-28]. The impact
of this lymphoid organization on autoantibody production
remains poorly understood, although an association between
circulating RFs and the presence of a synovial germinal center
reaction has been described [27,28] as well as dismissed
[29]. Our findings demonstrate for the first time that RA syno-
via containing lymphoid aggregates have significantly larger
amounts of RF-IgM and anti-CCP IgG, after normalizing for
serum content. It should also be noted that aggregate-contain-
ing tissues had autoantibody SSI values well above 1, indicat-
ing local synthesis and/or accumulation, whereas
autoantibody SSI in tissues with diffuse lymphoid infiltration
did not significantly differ from 1, suggesting the absence of
local production. In accordance with earlier findings [8], RA
synovia with lymphoid aggregates also contained elevated
immunoglobulin constant region mRNA but this did not trans-
late into a significant effect on total IgG or total IgM protein.
Finally, we determined the effect of rituximab on synovial
autoantibody and immunoglobulin levels in the longitudinal
ARISE study (described in detail earlier [6]). Despite the con-
siderable clinical improvement induced by rituximab treatment,
as well as the almost complete depletion of circulating B cells
[3,4], only modest, albeit significant, decreases in circulating
RF and anti-CCP were observed [5] and levels of these
autoantibodies were still highly elevated compared with nor-
mal controls. In the present study, similar results were
obtained. Furthermore, when all patients were considered
together, there was no significant effect of rituximab on syno-
vial content of any of the autoantibodies or immunoglobulin
studied, with the lone exception of IgG heavy constant region
message 8 weeks following rituximab infusion.
Of note, however, when patients were segregated according
to the presence or absence of lymphoid aggregates in their
synovia, the results were very different. Rituximab significantly
reduced immunoglobulin production at the mRNA level, as
well as total IgM and IgG content in synovia containing lym-
phoid aggregates, but not in synovia where lymphoid infiltra-
tion was diffuse. In spite of this, however, the treatment did not
have any effect on RF-IgM or anti-CCP IgG content in synovia
with lymphoid aggregates, even though these tissues pro-
duced massively increased levels of autoantibodies compared
with synovia with diffuse infiltration.
It is possible that the differential effect of rituximab on total
immunoglobulin and autoantibody synovial production is due
to a systematic change in the half-life of autoantibody-produc-
ing cells such that it may compensate for any effects of rituxi-
mab. More likely, however, and in light of the recent finding that
the size and number of synovial lymphoid aggregates in RA are
unaltered early after rituximab treatment [7], the aggregate
milieu might provide a protective niche for those B cells and
plasma cells that produce arthritis-associated autoantibodies.
In contrast, total immunoglobulins (presumably including dis-
ease-irrelevant antibodies) might be synthesized by B cells
and plasma cells that are more sensitive to rituximab treatment.
The existence of protective niches for certain classes of B
cells can be seen in a mouse model in which an anti-CD20
antibody ineffectively depleted peritoneal B cells, despite
almost complete removal of circulating B cells [30]. Similarly,
in macaques, rituximab depleted circulating and splenic B
cells, whereas the effect on B cells in lymph nodes and bone
marrow was variable [31]. We [6] and others [7] have shown
that rituximab significantly reduces synovial B cells in RA
patients, but the effect is highly variable and sometimes non-
existent, suggesting protection or replenishment of the syno-
vial B-cell pool. Recently, a more complete depletion of
synovial B cells by rituximab was demonstrated at a later time
point following treatment [32]; however, this could be
explained by an overall reduction of synovitis leading to a sec-
ondary effect on lymphocyte accumulation.Arthritis Research & Therapy    Vol 10 No 5    Rosengren et al.
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Conclusion
We developed quantitative methods for the determination of
synovial autoantibody and immunoglobulin enrichment in
biopsy materials obtained in clinical trials. Immunoglobulin
mRNA correlated with synovial protein levels, consistent with
local immunoglobulin synthesis. Both anti-CCP and RF-IgM
were significantly enriched in synovial tissues containing lym-
phoid aggregates. However, in an 8-week study, autoantibody
production in RA synovia was not altered by rituximab, whether
aggregates were present or not. In addition, aggregates sur-
vived treatment. Thus, synovial lymphoid architecture is cou-
pled with immunoglobulin and autoantibody production, but
the role of synovial ectopic lymphoneogenesis in the patho-
genesis and treatment of RA remains uncertain. It is unclear
whether these events are critical to pathogenesis or whether
they merely constitute epiphenomena of chronic inflammation.
Further studies in patients with earlier disease and using other
agents will be required to elucidate the contribution of synovial
antibody production and lymphoid architecture to RA
pathogenesis.
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